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Abstract: Genomic analysis could contribute to a better understanding of the biological determinants
of the evolution of multiple myeloma (MM) precursor disease and an improved definition of
high-risk patients. To assess the feasibility and value of next-generation sequencing approaches in an
asymptomatic setting, we performed a targeted gene mutation analysis and a genome-wide assessment
of copy number alterations (CNAs) by ultra-low-pass whole genome sequencing (ULP-WGS) in six
patients with monoclonal gammopathy of undetermined significance and 25 patients with smoldering
MM (SMM). Our comprehensive genomic characterization highlighted heterogeneous but substantial
values of the tumor fraction, especially in SMM; a rather high degree of genomic complexity, in terms
of both mutations and CNAs, and inter-patient variability; a higher incidence of gene mutations and
CNAs in SMM, confirming ongoing evolution; intraclonal heterogeneity; and instances of convergent
evolution. ULP-WGS of these patients proved effective in revealing the marked genome-wide level of
their CNAs, most of which are not routinely investigated. Finally, the analysis of our small SMM
cohort suggested that chr(8p) deletions, the DNA tumor fraction, and the number of alterations
may have clinical relevance in the progression to overt MM. Although validation in larger series
is mandatory, these findings highlight the promising impact of genomic approaches in the clinical
management of SMM.
Keywords: multiple myeloma; premalignant stages; next-generation sequencing
Cancers 2020, 12, 1332; doi:10.3390/cancers12051332 www.mdpi.com/journal/cancers
Cancers 2020, 12, 1332 2 of 12
1. Introduction
The recent progress in next-generation sequencing (NGS) techniques applied to multiple myeloma
(MM) has prompted comprehensive characterizations of genomic alterations in malignant plasma cells
(PCs) through clinical-grade approaches [1,2]. Different types of genomic lesions may contribute to
myelomagenesis and have a prognostic impact. Their detection, however, currently requires the use of
multiple molecular techniques (fluorescence in situ hybridization (FISH), Sanger sequencing, and single
nucleotide polymorphism arrays), which makes analysis expensive and technically demanding.
Furthermore, a large number of PCs is required. This may represent a limitation, especially in the
pre-malignant stages of the disease, i.e., monoclonal gammopathy of undetermined significance
(MGUS) and smoldering MM (SMM). MGUS and SMM, in fact, are characterized by a lower tumor
burden than overt MM. Therefore, a poor recovery of clonal CD138+ cells from the bone marrow (BM)
biopsy may preclude a thorough genomic characterization of these patients. On the contrary, genomic
analysis is proving increasingly important for better understanding the biological determinants of the
evolution of MM precursor clinical entities [3–5] and this could translate into a more effective definition
of patients at high-risk for progression, thus maximizing the benefit of early treatment [6,7]. While
whole-genome sequencing approaches cannot be employed in routine clinical care due to their cost
and turnaround time, several groups have shown the accuracy of custom target NGS solutions for a
streamlined detection of copy number abnormalities (CNAs), translocations at immunoglobulin heavy
chain (IGH) locus, and gene mutations in MM [8–12]. These approaches have mainly been evaluated
for patients with overt MM. Here, we present an extensive NGS-based genomic characterization of
asymptomatic form cases, i.e., six MGUS and 25 SMM patients, assessing its accuracy compared to
gold standard diagnostic techniques and its prognostic value compared to the risk stratification criteria
currently based on laboratory values.
2. Results
2.1. Tumor Load and Tumor Mutational Burden
Ultra-low pass whole-genome sequencing (ULP-WGS) and ultra-deep targeted NGS of a 56-gene
panel were performed at an average coverage across all samples of 0.1× and 3062×, respectively.
Our targeted panel identified a median of one mutation per patient in MGUS (range: 0–4) and two in
SMM (range: 0–9), without a statistically significant difference between the distributions of the two
groups (Figure 1a). Approximately one third of patients were devoid of mutations in the sequenced
genes, with similar proportions in MGUS and SMM. In asymptomatic cases, the detection of somatic
gene mutations in BM CD138+ cells could be undermined by the presence of normal PCs in the sample.
To address this issue, we estimated the tumor fraction by ichorCNA analysis of ULP-WGS data for
each patient, and correlated it to the number of variants identified. No correlation was identified
(Figure 1b), and many patients did not carry any mutation, despite a high tumor fraction (over 25% in
7/10 non-mutated cases). This suggests that, at this depth of sequencing, the test is sensitive enough to
account for contamination of the sample and return accurate results. On the other hand, the occurrence
of mutations with considerable allelic frequencies in patients with very low estimated tumor fractions is,
in all likelihood, justifiable with the fact that, since ichorCNA estimates the percentage of tumor-derived
DNA based on the detection of somatic CNAs, this analytical tool may underestimate tumor fractions
in patients devoid of clonal CNAs (as non-hyperdiploid, IGH-translocated asymptomatic stages are
likely to be). In general, tumor fractions were distributed over a wide range of values, and were
globally higher in SMM (median: 60%, range: 0–86.5%) than in MGUS (median: 8%, range: 0–68.5%)
(Wilcoxon rank sum test, p = 0.038, Figure 1c). Tumor fractions did not significantly correlate with BM
PC infiltration (Figure S1).
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Figure 1. Relationship between the tumor fraction, mutation burden, and disease stage. (a) Number 
of detected mutations in six monoclonal gammopathy of undetermined significance (MGUS) and 25 
smoldering multiple myeloma (SMM) patients. (b) The number of called mutations in genomic DNA 
from CD138+ bone marrow (BM) plasma cells of each patient did not correlate with the estimated 
tumor fraction. (c) Density plot of estimated tumor fractions in six MGUS and 25 SMM patients. 
2.2. Mutational Landscape 
Our targeted NGS approach identified mutations in 68% of patients (21/31) and in half of the 
genes included in the design (Figure 2; Table S1). Positive patients more often carried multiple 
variants (chi-square test, p = 0.012) involving different genes; the most extensively mutated patient 
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2.2. Mutational Landscape
Our targeted NGS approach identified mutations in 68% of patients (21/31) and in half of the
genes included in the design (Figure 2; Table S1). Positive patients more often carried multiple variants
(chi-square test, p = 0.012) involving different genes; the most extensively mutated patient was ID#143,
for whom we identified nine variants in seven genes. In terms of the mutation type, variants were
mostly missense variants. The KRAS gene was mutated in 19.4% of patients (6/31); NRAS and SP140
in 12.9% (4/31 each); and DUSP2, FGFR3, and IGLL5 in 9.7% (3/31 each). Out of the 66 mutations,
31 were clonal and 35 subclonal (so defined if involving ≥90% or <90% of the tumor fraction estimated
by ULP-WGS, respectively). Notably, mutated samples more often carried co-occurring clonal and
subclonal variants, even within the same gene. Of note, KRAS was targeted by multiple mutations
in three patients. In particular, we found clonal Q61H and subclonal K117N and Q22K in ID#99;
G12C, G12D, and Y64D, all at subclonal levels, in ID#143; and clonal G13D and Q61H and subclonal
G12V in ID#153. Interestingly, each of these three patients carried one or more additional mutated
genes belonging to the mitogen-activated protein kinase (MAPK) pathway, i.e., NRAS (subclonal Q61R
in ID#99, Q61K in ID#143, and Q61L in ID#153) and BRAF (subclonal V600E in ID#143) (Figure S2).
Altogether, these data support a complex and spontaneously evolving subclonal structure of MM, even
in an asymptomatic setting, with instances of convergent evolution and high-risk lesions of prognostic
value in case treatment is initiated.
2.3. Chromosomal Alterations
For a comprehensive view of the genomic alterations in our cohort, we characterized recurrent IGH
translocations by FISH and genome-wide CNAs by ichorCNA analysis of ULP-WGS data. Information
related to IGH translocations and selected CNAs recurrently associated with MM are visualized in the
upper heatmap in Figure 2, while Figure 3a and Figure S3 depict genome-wide CNAs. Four and two
SMM patients carried t(11;14) and t(4;14), respectively. Concerning CNAs, the hyperdiploid status
(defined as trisomy of two out of odd chromosomes 3, 5, 7, 9, 11, 15, 19, and 21) was the most recurrent
one, occurring in 68% of patients. The median number of involved odd chromosomes present in
extra copies was four and five in hyperdiploid MGUS and SMM cases, respectively. The other most
recursively detected lesions were 1q gain/amplification (42% of cases), del(13q) (35%), del(8p) and
del(16q) (19% each), del(1p) (16%), and del(14q) and del(6q) (13% each). The incidence of these CNAs
was higher in SMM than in MGUS (Wilcoxon rank sum test, p = 0.04). Interestingly, we found instances
of bi-allelic events in ZNF292 in ID#103, DIS3 in ID#68, TP53 in ID#144, and CYLD in ID#060, which is a
finding often associated with advanced stages [13]. CNAs at 1p, 1q, and 17p, as predicted by ULP-WGS,
were compared with FISH data, available for the 25 SMM patients and based on signals obtained in
purified BM PCs at cytobands 1p32, 1q21, and 17p13, respectively (Figure 3b–d). We found almost
full concordance in terms of gains/amplifications detected by FISH and ULP-WGS at chromosome
arm 1q (Figure 3b,c), with the exception of two samples, in which the gain, harbored by 6% and 8% of
interphase nuclei, respectively, was not detected by ULP-WGS. In agreement with FISH, ULP-WGS
revealed a deletion of 17p13.1-pter in patient ID#144. However, it failed to detect a 17p13 monoallelic
deletion found in very small subclones in three FISH-positive patients (7% of positive cells in ID#143,
11% in ID#99, and 12% in ID#104), as well as in two samples in which FISH identified 62% (ID#53) and
41% (ID#66) of positive cells, respectively. Since the percentages of FISH-positive cells were quite high,
and therefore theoretically appreciable by ULP-WGS, we believe that this discrepancy in the latter
two samples may depend on very focal deletions which have been reported to occur [14]. Therefore,
ULP-WGS analysis by ichorCNA, which, by default, computes log2 copy ratios for genomic windows
of 1Mb [15], may miss the deletion. To verify this hypothesis, we re-analyzed the ULP-WGS data of
these two samples by ichorCNA, setting genomic windows equal to 50 kb. In this way, we managed
to detect the deletion in both patients, confirming its limited extension (1.7 Mb in ID#53 and 5.9 Mb
in ID#66, respectively) and the involvement of the TP53 gene (Figure S4). Furthermore, ULP-WGS
was able to provide more information than FISH concerning interstitial deletions of chromosome arm
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1p (Figure 3d). Both methods detected a deletion in sample ID#66. In four additional FISH-negative
patients, ichorCNA identified interstitial 1p deletions with centromeric localization compared to the
probe used for FISH, and mapping at 1p21.3-p31.1 (ID#060), 1p12-p13.2 (ID#100), 1p21.2-p31.3 (ID#136),
and 1p12-p22.3 (ID#165), respectively. We confirmed these 1p interstitial deletions as true events by
using targeted sequencing data of the 56-gene panel (Figure S5).
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Figure 2. Overview of genomic aberrations and gene mutations in asymptomatic multiple myeloma. 
(a) Heatmap of selected chromosomal copy number alterations (CNAs), as assessed by ultra-low-pass 
whole genome sequencing (ULP-WGS), and immunoglobulin heavy chain locus (IGH) chromosomal 
translocations, as assessed by fluorescence in situ hybridization (FISH), in the six MGUS and 25 SMM 
patients. Only CNAs occurring in ≥4 samples are plotted; chromosome arms within which the CNAs 
Figure 2. Overview of genomic aberrations and gene mutations in asymptomatic multiple myeloma.
(a) Heatmap of s lect d chromosomal copy nu ber alterations (CNAs), a assessed by ultra-low-pass
whole genome sequencing (ULP-WGS), and immunoglobulin heavy chain locus (IGH) chromosomal
translocations, as assessed by fluorescence in situ hybridization (FISH), in the six MGUS and 25 SMM
patients. Only CNAs occurring in ≥4 samples are plotted; chromosome arms within which the CNAs
(with variable extensions) localize are indicated. Gray squares indicate an absence of alterations,
and black ones indicate their occurrence. (b) Mutated genes, color coded for missense (red), splice-site
(light blue), nonsense/frameshift (green), indel (orange). A diagonal bar highlights mutations occurring
in a gene with a copy number of 1. In the case of multiple variants detected, the squares are countered
in black. A smaller internal yellow square denotes subclonal mutations. Only genes mutated in at
least one sample are plotted. Each column represents one tumor sample and each row represents
one chromosomal alteration/gene. MGUS samples are indicated in yellow, and SMM samples in lilac.
The percentage of tumors carrying each alteration is provided on the right.
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Figure 3. Chromosomal alterations charact i g the genome of asymptomatic multiple yeloma.
(a) Circos plot showing genome-wide copy number abnormalities (from ULP-WGS) and chromosomal
translocations involving the IGH locus (from FISH analysis) found in tumor samples from six MGUS
and 25 SMM patients. Autosomes are arranged around the circle, starting from the top at chromosome 1
and continuing clockwise to chromosome 22. Copy number data are presented on the inside of the circle,
showing gains/amplifications (first track, red), normal copy number (second track, grey), and deletions
(third tack, light blue). Immunoglobulin heavy chain locus (IGH@) translocations are shown as green
lines emerging from chr mosome 14 to their respective partner chromosomes. The color intensity of
gained and lost segments and the ick ess of the lines indicating IGH translocations heighten with an
increasing frequency of that anomaly in the cohort. (b) Heatmap representing the percentage of cells
carrying each of the indicated chromosomal copy number alterations, as detected by FISH analysis.
Each column represents one tumor sample and each row represents one CNA. Samples that tested
positive for the corresponding lesion by ULP-WGS analysis are framed. N.a., not available. (c) Bar
graphs representing the percentage of cells carrying each of the indicated chromosomal copy number
alterations, as detected by FISH analysis (left vertical axis), in the 25 SMM pati nts. IchorCNA-estimated
tumor fractio in th plasma cell (PC) gDNA of e ch patient is indicated b a l ght-blue circle (right
vertical axis). Samples that tested positive for the corresponding lesio y ULP-WGS analysis are
framed. (d) Chromosome 1 copy ratios computed by ichorCNA from ULP-WGS data in four patients
(marked by an asterisk in b) tested negative for del(1p) by FISH analysis. Amplification (red), loss
(green), and copy neutral (blue) are indicated. The horizontal lines in light green indicate subclonal
calls. The vertical red bar marks the location of the FISH probe. The main genes mapped in the deleted
region in each patient are listed in the lower part of the figure.
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2.4. Prognostic Value of Genomic Findings
We then assessed whether the information obtained from targeted NGS and ULP-WGS showed
any correlation with the clinical outcome of the patients, restricting the analysis to the 25 SMM cases.
Gene mutations did not correlate with time to progression: this applied to the type of gene, to the
number of genes mutated, and to their allelic fraction. However, we found that patients with a tumor
fraction higher than 67% (i.e., the tumor fraction value identified by an ROC analysis as the best
discriminating cut-off between progressing and non-progressing cases) had a significantly shorter time
to progression (TTP) (median of 16 months vs. not reached, p = 0.0053) (Figure 4a). Concerning CNAs,
the occurrence of chromosome 8p deletion seemed to be associated with a more rapid progression
to symptomatic MM (median of 11 months vs. not reached, p = 0.02) (Figure 4b). The percentage of
BM PCs correlated with the risk of progression, as expected. However, the recently proposed risk
classification of SMM stratifying patients into three groups based on the occurrence of BMPC > 20%,
M-protein > 2 g/dL, and free light chain ration (FLCr) > 20 (20/2/20 model) [16], was not able to
discriminate different intervals of TTP in our small series. To assess whether the information obtained
from our genomic analysis might have some relevance in the context of current prognostic models
based on surrogates of tumor burden, we tried to integrate the 20/2/20 model with the tumor fraction
estimate. We found that by assigning an additional point to patients with a DNA tumor fraction higher
than 67%, the high-risk group (score ≥ 3) had a significantly shorter TTP (median of 12 months vs. not
reached, p = 0.011) (Figure 4c). Lastly, when we combined mutational data with genome-wide CNAs,
we found that the presence of two or more events (mutations and/or CNAs) was associated with faster
disease progression (median of 51 months vs. not reached, p = 0.027) (Figure 4d).
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Figure 4. Kaplan–Meier curves of ti e r r ssi n ( TP) by next-g neration seque cing
(NGS)-derived molecular information in SMM. Kaplan–Meier curves of TTP according to the
ichorCNA-estimated tumor fraction of bone marrow (BM) plasma cell (PC) genomic DNA (a),
the occurrence of deletions in chromosome arm 8p (b), the 20/2/20 model integrated with the tumor
fraction of BM PC genomic DNA (c), and the number of mutational and CNA events carried by each
patient (d).
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3. Discussion
Monoclonal gammopathy of undetermined significance (MGUS) and SMM represent intermediate
steps in the development of overt MM. MGUS progresses at a constant and low rate of 1%/year [17].
SMM is clinically more heterogeneous, including both MGUS-like and MM-like patients at a high risk
of developing a myeloma-defining event within the first 2 years of diagnosis [18]. Different clonal
evolution patterns characterizing these two clinical subsets of SMM patients have been identified by
recent NGS studies [5,19]. It follows that genomic analysis could contribute to a better understanding
of the biological basis of the evolution of MM precursor disease, as well as a refinement of the definition
of high-risk patients. To assess the feasibility and value of such studies, in this research we performed
a targeted gene mutation analysis and a genome-wide CNA assessment aimed at a comprehensive
view of genomic alterations in six MGUS and 25 SMM patients.
Our series of asymptomatic cases was characterized by heterogeneous but substantial values of
the tumor fraction, especially in SMM. This was independent of the number of mutations identified in
each sample, which ensures the reliability of our data and supports the use of NGS approaches for
an in-depth genomic characterization of these patients. Overall, our analyses of asymptomatic forms
revealed a rather high degree of genomic complexity, in terms of both mutational and chromosomal
aberrations, and inter-patient variability. The median number of variants was one in MGUS and two
in SMM patients. SMM patients presented a higher incidence of CNAs and specific aneuploidies in
hyperdiploid samples, confirming the ongoing evolution in these asymptomatic stages, as reported in
preliminary reports based on FISH [20]. More recent high-throughput studies showed that MGUS
is less genetically complex than MM, and high-risk SMM is similar to presenting MM in terms of
mutations [21] and CNAs [22]. In SMM samples, we observed a somewhat binary distribution, whereby
patients either showed no mutations or multiple mutations. The mixture of clonal and subclonal events
concerning both gene mutations and CNAs in the majority of patients was suggestive of intraclonal
heterogeneity, confirming that this is a feature of all disease stages [5,21,23]. Interestingly, while the
six MGUS patients were devoid of mutations in genes of the MAPK pathway, this was recurrently
targeted in SMM cases, with KRAS and NRAS being the two top-ranking genes in terms of mutational
incidence. An SMM sample also carried a BRAF V600E mutation. Furthermore, our in-depth analysis
highlighted examples of convergent evolution that included multiple mutations within the same
gene or pathway found in the same patient: among these, there were three cases harboring MAPK
mutations, and one patient with two TP53 mutations, similar to what has been reported in the
symptomatic setting [24–27]. ULP-WGS has proven to be effective in highlighting how the karyotype
of asymptomatic patients is altered at the genome-wide level, also detecting recurrent CNAs that are
not routinely investigated by FISH. This allowed us to identify tumor suppressor genes, such as TP53
and CYLD, which were frequently hit by bi-allelic events, something previously described in advanced
disease. Furthermore, interstitial deletions in chr(1p) not detected by FISH could be identified by
ULP-WGS, further confirming how genomic approaches can outperform FISH [4]. Although ULP-WGS
showed a reduced sensitivity in the detection of highly subclonal deletions, this is likely to be of little
relevance in laboratory and clinical routine practice, since the current threshold for the detection of
FISH events is 10% and even much higher according to consensus criteria for chr(17p) deletion [28].
Interestingly, the more extensive information provided by the ULP-WGS approach appears to be of
clinical value in our small SMM cohort. In fact, we could assign a prognostic value to chr(8p) deletions;
to the tumor fraction of purified BM PCs; and, in general, to the number of genomic events, mutations,
and/or CNAs, either alone or in combination with the revised IMWG SMM risk stratification. Although
the limited size of the present cohort and the lack of validation in larger independent series impose
caution in extending the validity of the specific clinical correlates identified, these findings highlight
the promise of genomic approaches in the clinical management of SMM.
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4. Materials and Methods
4.1. Patients
The study was based on a series of six patients with MGUS and 25 with SMM admitted to
our institution. MGUS and SMM were diagnosed according to the International Myeloma Working
Group (IMWG) revised criteria [29] and SMM patients were stratified by recently proposed risk
factors for progression [16]. Patients‘ clinical and molecular characteristics are reported in Table
S2. None of the patients enrolled in this study had previously received anti-MM therapy, and in all
cases, sampling was done under conditions of clinically stable disease. The study was approved
by the local Ethics Committee (Provision n.575 dated 29/03/2018) and written informed consent was
obtained from all of the patients involved in the study. The study was conducted according to good
clinical practice and the ethical principles outlined in the Declaration of Helsinki. BM mononuclear
cells (MNCs) were obtained from BM aspirates, after gradient centrifugation with Ficoll solution
(Lympholyte® Cell Separation Media, Cedarlane, Canada). CD138+ PCs were isolated from BM
MNCs by an immunomagnetic method with anti-CD138 monoclonal antibodies (mAbs) conjugated
with microbeads (Miltenyi Biotech; Bergisch-Gladbach, Germany). For the purification of genomic
DNA, we used the AllPrep DNA/RNA/miRNA isolation kit (Qiagen, Hilden, Germany), following the
manufacturer’s protocol.
4.2. Next-Generation Sequencing
We collected tumor gDNA from CD138+-purified BM PCs. The targeted resequencing gene panel
included coding exons and splice sites of 56 genes that emerged as drivers from a recent analysis
of whole genome/exome data in more than 800 MM patients [30] (target region: 112 kb: ACTG1,
BCL7A, BHLHE41, BRAF, BTG1, CCND1, CDKN1B, CYLD, DIS3, DTX1, DUSP2, EGR1, FAM46C, FGFR3,
FUBP1, HIST1H1B, HIST1H1D, HIST1H1E, HIST1H2BK, IGLL5, IRF1, IRF4, KLHL6, KMT2B, KRAS,
LCE1D, LTB, MAX, NFKB2, NFKBIA, NRAS, PABPC1, PIM1, POT1, PRDM1, PRKD2, PTPN11, RASA2,
RB1, RFTN1, RPL10, RPL5, RPRD1B, RPS3A, SAMHD1, SETD2, SP140, TBC1D29, TCL1A, TGDS,
TP53, TRAF2, TRAF3, XBP1, ZNF462, ZNF292). Ultra-deep NGS was performed on MiSeq (Illumina,
Hayward, CA, USA) using the CAPP-seq library preparation strategy (NimbleGen, Roche, Madison,
WI, USA), as previously described [31,32]. The germline function of VarScan2 mpileup2cns was used to
identify non-synonymous somatic mutations, and a stringent bioinformatic pipeline was developed
and applied to filter out sequencing errors (detection limit 3 × 10−3). Details of the experimental
procedures are given in Supplementary Methods. For ULP-WGS, libraries were prepared using the
Kapa HyperPlus kit (Roche, Madison, WI, USA) with SeqCap Library Adapters starting with 400 ng
of gDNA. Up to 24 libraries were pooled and sequenced using 200 bp paired-end runs on a MiSeq
(Illumina). In order to estimate the quality and presence of a tumor, we performed ULP-WGS with an
average genome-wide fold coverage of 0.1×. We analyzed the depth of coverage to estimate large-scale
CNAs and the fraction of tumor DNA using ichorCNA [15] with a panel of 34 normal samples.
4.3. Fluorescence In Situ Hybridization (FISH) Analysis
Interphase FISH analyses were performed as previously described [33] on purified BM PCs.
4.4. Statistical Analyses
Time to first progression (TTP) was calculated from diagnosis to the first occurrence of any
myeloma-defining event (event) or to last follow-up (censoring). TTP analyses were performed using
the Kaplan–Meier method. The statistical significance of associations between individual variables
and TTP was calculated using the log-rank test.
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5. Conclusions
Overall, our findings demonstrate that, starting from a limited amount (400 ng) of DNA from
purified BM PCs of asymptomatic patients, a highly informative genomic analysis is feasible. To entirely
replace FISH, in the future, more sophisticated targeted designs could be conceived, including
chromosomal regions of recurrent CNAs and the IGH locus, to enable the detection of IGH translocations.
Preliminary studies have proven promising in this setting [8–12]. Alternatively, as sequencing costs will
decrease, CNAs and IGH translocations could be detected by a shallow, long-insert WGS. This would
also produce data on the tumor fraction, which proved to be prognostically relevant in our series.
Although the presented data need validation in an independent cohort, the finding that the tumor
fraction did not correlate with the percentage of plasma cell infiltration in the BM makes its prognostic
value even greater, and suggests that it may be worthwhile to consider it to improve current SMM
risk stratification.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/5/1332/s1:
Supplementary Methods; Figure S1: Tumor fraction and BM PC infiltration; Figure S2: MAPK gene mutations;
Figure S3: Heatmap of altered DNA regions in six MGUS and 25 SMM samples, as assessed by means of ichorCNA
analysis of ULP-WGS data; Figure S4: Detection of TP53 gene deletion by ichorCNA analysis of ULP-WGS
data; Figure S5: Detection of 1p-deletions based on targeted NGS data; Table S1: Non-synonymous mutations
discovered by targeted gene mutation analysis; Table S2: Patients’ characteristics.
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